Lotus Bio

Lotus Bio-Technology is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of advanced cell therapies for oncology and regenerative medicine. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor (TCR-T) technologies to treat hematological malignancies and challenging solid tumors. Lotus Bio-Technology operates a proprietary platform designed to optimize cell engineering and manufacturing processes, aiming to improve the efficacy and safety of immunotherapy. Their pipeline includes several candidates targeting CD19 and BCMA, with ongoing clinical trials in China and international collaborations. Beyond oncology, the company explores the potential of stem cell-based therapies for various degenerative conditions.